Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor.

This tolerability study revealed that despite a mild toxicity profile, cipatinib was well tolerated up to the anticipated maximum dosage of 1800 mg/m2 . Further clinical trials are warranted.